Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hedge Fund Winners in FDA Panel’s Regeneron Decision $REGN

Regeneron (REGN) shares were halted earlier today before an FDA panel’s decision about Regeneron’s new eye medicine. Here is what Reuters says:

Regeneron Pharmaceuticals Inc (NASDAQ:REGN)

A new eye medicine from Regeneron Pharmaceuticals (REGN) and Bayer AG was a safe and effective way of treating vision loss from macular degeneration, a U.S. advisory panel unanimously said on Friday.

The advisers to the Food and Drug Administration also said the drug, to be marketed as Eylea, could be dosed once every two months, giving it an edge over the typical monthly dosing of its chief competitor, Lucentis, from Roche Holding .

“The data is very compelling for equivalence (with Lucentis),” said Dr. Lynn Gordon, a panel member and associate professor in the department of ophthalmology at the University of California in Los Angeles.

The FDA usually approves medicines that win advisory panel backing and is expected to rule on Eylea by Aug. 20. The panel voted 10-0 in favor of the medicine.

There were several hedge funds that were bullish about Regeneron before this decision is announced. Here are the winners:

1. Carl Icahn – Icahn Capital: Had $109 Million in REGN at the end of March.

2. Jacob Gottlieb – Visium Asset Management: Had$55 Million in REGN at the end of March.

3. Daniel Gold – QVT Financial: Had$52 Million in REGN at the end of March.

4. Arthur Cohen and Joe Healey – HealthCor: Had$9 Million in REGN at the end of March.

5. Samuel Isaly – OrbiMed Advisors: Had $4 Million in REGN at the end of March.

Regeneron gained 26.2% between April 1st and June 16th. So Carl Icahn already made $29 Million before the FDA panel’s decision.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!